This phase 1 randomized, single-center clinical trial evaluated the safety and immunogenicity of inactivated influenza virus vaccine delivered via dissolvable microneedle patches (MNPs). Comparing humoral and cellular responses in participants receiving vaccination by MNP versus intramuscular (IM) injection, researchers found similar hemagglutination inhibition (HAI) titers and antibody avidity, despite a lower antigen dose in the MNP group. MNPs, however, generated higher neuraminidase inhibition (NAI) titers and a larger percentage of circulating T follicular helper cells than IM vaccination. The study concludes that MNP delivery produces comparable or superior humoral and cellular immune responses to IM injection.
Publisher
npj Vaccines
Published On
Jul 14, 2021
Authors
Nadine G. Rouphael, Lilin Lai, Sonia Tandon, Michele Paine McCullough, Yunchuan Kong, Sarah Kabbani, Muktha S. Natrajan, Yongxian Xu, Yexun Zhu, Dongli Wang, Jesse O'Shea, Amy Sherman, Tianwei Yu, Sebastian Henry, Devin McAllister, Daniel Stadlbauer, Surender Khurana, Hana Golding, Florian Krammer, Mark J. Mulligan, Mark R. Prausnitz
Tags
influenza vaccine
microneedle patches
immunogenicity
safety
clinical trial
humoral response
cellular response
Related Publications
Explore these studies to deepen your understanding of the subject.